CS
BBIO icon

Credit Suisse’s BridgeBio Pharma BBIO Stock Holding History

Credit Suisse’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3.1M Buy
100,354
+9,398
+10% +$320K ﹤0.01% 1583
2023
Q4 		$3.67M Sell
90,956
-631,783
-87% -$19M ﹤0.01% 1513
2023
Q3 		$19.1M Sell
722,739
-46,007
-6% -$1.31M 0.02% 655
2023
Q2 		$13.2M Buy
768,746
+35,918
+5% +$540K 0.01% 804
2023
Q1 		$12.2M Buy
732,828
+214,727
+41% +$2.5M 0.01% 852
2022
Q4 		$3.95M Sell
518,101
-90,927
-15% -$871K ﹤0.01% 1452
2022
Q3 		$6.05M Buy
609,028
+36,458
+6% +$379K 0.01% 1148
2022
Q2 		$5.2M Sell
572,570
-42,955
-7% -$359K 0.01% 1258
2022
Q1 		$6.25M Sell
615,525
-54,211
-8% -$556K 0.01% 1320
2021
Q4 		$11.2M Buy
669,736
+202,610
+43% +$8.57M 0.01% 1414
2021
Q3 		$21.9M Buy
467,126
+75,118
+19% +$4.03M 0.01% 1048
2021
Q2 		$23.9M Buy
392,008
+25,029
+7% +$1.43M 0.01% 1063
2021
Q1 		$22.6M Buy
366,979
+27,919
+8% +$1.83M 0.01% 1097
2020
Q4 		$24.1M Sell
339,060
-123,027
-27% -$5.94M 0.01% 1068
2020
Q3 		$17.3M Sell
462,087
-84,914
-16% -$2.67M 0.01% 1108
2020
Q2 		$17.8M Buy
547,001
+536,945
+5,340% +$16.4M 0.01% 999
2020
Q1 		$292K Sell
10,056
-12,176
-55% -$378K ﹤0.01% 3441
2019
Q4 		$780K Buy
+22,232
New +$616K ﹤0.01% 3290
2019
Q3 		– Sell
-26,000
Closed -$701K – 4108
2019
Q2 		$701K Buy
+26,000
New +$709K ﹤0.01% 3191

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Credit Suisse's BBIO Position: Q1 2024 in Review

Credit Suisse increased its BridgeBio Pharma (BBIO) stake by 10% in Q1 2024, buying an estimated $320K and bringing the position to 100,354 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1583.

Credit Suisse first reported a position in BBIO in Q2 2019 and has held it in 19 quarters since. The position peaked at $24.1M in Q4 2020. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

  • Credit Suisse held 100,354 shares of BridgeBio Pharma worth $3.1M as of Q1 2024.
  • Credit Suisse bought 9,398 BridgeBio Pharma shares in Q1 2024, an estimated $320K.
  • BridgeBio Pharma made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1583 holding.
  • Credit Suisse first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 19 quarters since.
  • Credit Suisse's BridgeBio Pharma position peaked at $24.1M in Q4 2020.
  • 244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.